Skip to content
User

Daniel Loeb

Third Point

Daniel Loeb Amgen Inc stake

total: 588

Third Point AMGN trades

Total transactions:
9
New positions:
1
Sold out:
1
Added:
3
Reduced:
4
Held since:
2014 Q2
Held for:
8 quarters
Latest activity:
2016 Q2
According to 2026 Q2 report, Daniel Loeb doesn't hold any Amgen Inc (AMGN) shares. To date, the estimated cost basis is nearly $154.72 for "buy" trades and estimated average "sell" price is $151.69. Third Point first purchased AMGN in 2014 Q2, initially acquiring 450,000 shares. Since the initial investment in Amgen Inc (AMGN), Third Point has made 8 more transactions.

When did Daniel Loeb sell Amgen Inc (AMGN)?

Daniel Loeb sold off the entire Amgen Inc (AMGN) position in 2016 Q2.

When did Daniel Loeb buy Amgen Inc (AMGN)?

Daniel Loeb first invested in Amgen Inc (AMGN) in 2014 Q2 at the reported quarter-end price of $118.37 per share.

What's the cost basis of Third Point's AMGN stake?

The estimated cost basis for Amgen Inc (AMGN) stake is around $154.72 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$154.72
Weighted AVG sell price:
$151.69

Daniel Loeb's historical trades in Amgen Inc

9 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2016 Q2
0.00%
$149.93
-100% (-3,000,000)
2016 Q1
4.21%
$149.93
-66.82% (-6,042,900)
2015 Q4
14.89%
$162.33
-8.19% (-807,100)
2015 Q3
13.13%
$138.32
+9.44% (+850,000)
2015 Q2
13.54%
$153.52
-10.00% (-1,000,000)
2015 Q1
15.86%
$159.85
-6.32% (-675,000)
2014 Q4
15.34%
$159.29
+705.66% (+9,350,000)
2014 Q3
2.23%
$140.46
+194.44% (+875,000)
2014 Q2
0.66%
$118.37
new
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.